Enavogliflozin

依那格列净

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NameEnavogliflozin
Drug Alias NameEnvloDWP-16001GCC-5694A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitors
TargetsSodium/glucose cotransporter 2
Therapy Area/IndicationsEndocrine System DiseasesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1 +[9] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2022/11/30
Country/TerritoryUnited StatesMexicoSouth Korea +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesDaewoong Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesM8 Pharmaceuticals IncDaewoong Pharmaceutical Co LtdVanderbilt University Medical Center +[5] 
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus +[8] 
Inactive IndicationsEndocrine System Diseases

Other Information

ATC CodeA10BK
Related LinksN/A